BEACON introduces yet another blockbuster anticancer drug, Lenvatinib

BEACON introduces another promising multikinase inhibitor, Lenvatinib, under the brand name of Lenvanix for global market.

  • First new Front-Line treatment option for Hepatocellular Carcinoma (HCC).

  • First Tyrosine Kinase Inhibitor (TKI) for locally recurrent or metastatic, progressive RAI-refractory Differentiated Thyroid Cancer (DTC).

  • Lenvatinib plus everolimus is the first and only FDA-approved regimen for advanced Renal Cell Cancer (RCC) treatment.

   Lenvanix is an oral capsule preparation which is available in the strengths of 10 mg & 4 mg. 

To know more visit our product website: